Martha E. Manning - Feb 20, 2024 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC. (MRNS)

Role: SVP, GEN. COUNSEL & CORP. SEC.
Signature: /s/ Debra A. Mohollen, Attorney-in-Fact
Stock symbol: MRNS
Transactions as of: Feb 20, 2024
Transactions value $: -$18,126
Form type: 4
Date filed: 2/22/2024, 04:05 PM
Previous filing: Jan 19, 2024
Next filing: Jun 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNS	Common Stock	Sale	-$18.1K	-1.89K	-3.45%	$9.57	53K	Feb 20, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
F2	The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.